Abstract
A growing body of evidence supports that DNA methylation-mediated silencing of tumor suppressor genes plays a significant role in cancer development. DNA methylatransferase (DNMT) is the enzyme catalyzing the methylation modification of cytosines in a CpG dinucleotide context. In humans, this reaction is highly selective for certain gene promoters and/or genomic DNA domains. Elucidation of the intracellular targeting mechanism by DNMT has become the key task for understanding epigenetic regulation in cancers. Unfortunately, no suitable method is available to explore this important cell function. This study focuses on the development of an efficient technique for measuring the intracellular, DNMT isoform-specific, and methylated gene-specific, DNA methylation alterations. The technique, designated IMA for Intracellular DNA Methylation Assay, takes advantage of covalent arresting of active DNMT molecules by aza-deoxycytidine (ADC), a modified cytosine homologue readily incorporated into genomic DNA at the cytosine position. The DNMT-DNA complex was isolated by a modified ETOH precipitation procedure to remove cellular proteins including free DNMT. Chromatin immunoprecipitation using DNMT isoform-specific antibody was subsequently performed to collect DNMT-bound DNA fragments. PCR amplification was used to detect and quantify the isolated gene fragment. Validation of the IMA was performed by manipulating the DNMT activity, by treating with antisense oligonucleotides against DNMT1 and DNMT3B, and repeating the IMA experiment. One of the main discoveries with this technique was the observation of DNMT3B maintenance methylation activity. This new technique can be applied to examine the dynamic DNMT-specific action on diversified methylation-silenced genes, in a variety of cell culture conditions.
Keywords: DNA methyltransferase, methylation assay, DNA methylation, epigenetic regulation.
Current Pharmaceutical Design
Title:Development of an Intracellular, DNA Methyltransferase-Specific, and Gene-Specific Assay for Studying Dynamic DNA Methylation
Volume: 20 Issue: 11
Author(s): Jesus Gonzalez-Bosquet, Yongli Chu, Hai Bin Chen, Sean C. Dowdy, Karl C. Podratz, Jinping Li and Shi-Wen Jiang
Affiliation:
Keywords: DNA methyltransferase, methylation assay, DNA methylation, epigenetic regulation.
Abstract: A growing body of evidence supports that DNA methylation-mediated silencing of tumor suppressor genes plays a significant role in cancer development. DNA methylatransferase (DNMT) is the enzyme catalyzing the methylation modification of cytosines in a CpG dinucleotide context. In humans, this reaction is highly selective for certain gene promoters and/or genomic DNA domains. Elucidation of the intracellular targeting mechanism by DNMT has become the key task for understanding epigenetic regulation in cancers. Unfortunately, no suitable method is available to explore this important cell function. This study focuses on the development of an efficient technique for measuring the intracellular, DNMT isoform-specific, and methylated gene-specific, DNA methylation alterations. The technique, designated IMA for Intracellular DNA Methylation Assay, takes advantage of covalent arresting of active DNMT molecules by aza-deoxycytidine (ADC), a modified cytosine homologue readily incorporated into genomic DNA at the cytosine position. The DNMT-DNA complex was isolated by a modified ETOH precipitation procedure to remove cellular proteins including free DNMT. Chromatin immunoprecipitation using DNMT isoform-specific antibody was subsequently performed to collect DNMT-bound DNA fragments. PCR amplification was used to detect and quantify the isolated gene fragment. Validation of the IMA was performed by manipulating the DNMT activity, by treating with antisense oligonucleotides against DNMT1 and DNMT3B, and repeating the IMA experiment. One of the main discoveries with this technique was the observation of DNMT3B maintenance methylation activity. This new technique can be applied to examine the dynamic DNMT-specific action on diversified methylation-silenced genes, in a variety of cell culture conditions.
Export Options
About this article
Cite this article as:
Gonzalez-Bosquet Jesus, Chu Yongli, Chen Bin Hai, Dowdy C. Sean, Podratz C. Karl, Li Jinping and Jiang Shi-Wen, Development of an Intracellular, DNA Methyltransferase-Specific, and Gene-Specific Assay for Studying Dynamic DNA Methylation, Current Pharmaceutical Design 2014; 20 (11) . https://dx.doi.org/10.2174/13816128113199990539
DOI https://dx.doi.org/10.2174/13816128113199990539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Beta-glucans is a Potential Inhibitor of Ovarian Cancer: Based on Molecular and Biological Aspects
Current Pharmaceutical Biotechnology An Overview of Pathogenesis and Pathophysiology in Endometriosis
Current Women`s Health Reviews Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Selective Estrogen Receptor Modulators. Current and Future Treatment Options for Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery The Immunohistochemical Expression of the E-Cadherin, Alpha-Catenin,Beta-Catenin and Gamma Catenin Proteins in Epithelial Ovarian Tumours: Relationship with Clinicopathologic Parameters and Patient Survival
Current Women`s Health Reviews Metabolism and Toxicological Implications of Commonly Used Chemopreventive Drugs Against Breast Cancer/Carcinogenesis
Current Drug Metabolism